

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12P 21/06, C12N 5/00, 15/00 A61K 49/00, C12Q 1/68		A1	(11) International Publication Number: WO 92/05273 (43) International Publication Date: 2 April 1992 (02.04.92)
(21) International Application Number: PCT/US91/06660			(74) Agents: LEWAK, Anna, M. et al.; Harness, Dickey & Pierce, P.O. Box 828, Bloomfield Hills, MI 48303 (US).
(22) International Filing Date: 16 September 1991 (16.09.91)			
(30) Priority data: 584,275 18 September 1990 (18.09.90) US			(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(71) Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN [US/US]; 475 East Jefferson, Room 2354, Ann Arbor, MI 48109-1248 (US).			Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventors: COLLINS, Francis S. ; 4340 Scio Church Road, Ann Arbor, MI 48103 (US). WILSON, James, M. ; 3686 River Pine Drive, Ann Arbor, MI 48103 (US).			

(54) Title: GENE THERAPY FOR CYSTIC FIBROSIS

(57) Abstract

The present invention comprises gene therapy for treating cystic fibrosis (CF). Delivery and expression of a single copy of a normal CFTR gene leads to stable correction of the Cl channel regulation defect present in CF epithelial cells. The present invention includes recombinant viral and plasmid vectors, alternative CFTR gene delivery strategies, and transduced CF cells and cell lines carrying a recombinant gene for functional CFTR. CF epithelial complementation through transduction of the present invention also provides an assay for determining the validity of other putative CF mutations.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	CN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU+	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in the States of the former Soviet Union.

GENE THERAPY FOR CYSTIC FIBROSIS
SPONSORSHIP

Work on this invention was supported by the Cystic Fibrosis Foundation and by the United States government under grants DK42718 and DK39690 awarded by the

5 National Institutes of Health. The government has certain rights in the invention.

RELATED APPLICATIONS

This an International Application, claiming benefit of U.S. application Serial No. 584,275, entitled "Gene Therapy for Cystic Fibrosis", filed September 18, 1990, which is a continuation-in-part of U.S. application Serial No. 401,609, entitled "Cystic Fibrosis

10 Gene", filed on August 31, 1989, which is a continuation-in-part of U.S. application Serial No. 399, 945, entitled "Cystic Fibrosis Gene", filed on August 24, 1989, now abandoned, which is a continuation-in-part of U.S. application Serial No. 396,894, entitled "Cystic Fibrosis Gene", filed on August 22, 1989, now abandoned, all of which applications are specifically incorporated by reference herein.

15

FIELD OF THE INVENTION

The present invention relates generally to gene therapy for cystic fibrosis (CF) and, more particularly, to transfer of the gene for cystic fibrosis transmembrane conductance regulator (CFTR) to correct the defect in epithelial cell Cl channel regulation in cystic fibrosis patients.

20

BACKGROUND OF THE INVENTION

Cystic fibrosis (CF) is an autosomal recessive disorder characterized by abnormalities in water and electrolyte transport that lead to pancreatic and pulmonary insufficiency. Taussig, L.M., An overview. In Cystic Fibrosis, L.M. Taussig, ed. (New York: Thieme-Stratton), 1-9 (1984). It is one of the most common severe autosomal 25 recessive disorders, having a 5% carrier frequency and affecting about 1 in 2500 live births in North America.

Functional expression of the CF defect reduces the chloride ion permeability of epithelial tissues. Quinton, P.M., *FASEB J.* 4:2709-2717 (1990). The ability of epithelial cells in the airways, sweat glands, pancreas and other tissues to secrete Cl 30 in response to cAMP-mediated agonists is lost or severely reduced. Activation of apical membrane Cl channels by cAMP-dependent protein kinase (PKA) is impaired, but channels with normal conductance properties can be activated by other means, including agonists whose effects are mediated by increased cell Ca. Frizzell, R.A. et al., *Trends Neurosci.* 10:190-193 (1987); Welsh, M.J., *FASEB J.* 4:2718-2725 (1990). 35 These findings suggest that the Cl channel *per se* is not defective in CF, but that the

defect might lie in a regulatory protein that transduces the effects of protein kinase activation. The presence of abnormalities in epithelial sodium transport in CF cells further supports the concept of a regulatory defect that can affect other cellular functions. Boucher, R.C. et al., *J. Clin. Invest.* 78:1245-1252 (1986).

5 Isolation of the gene for CF, as described in detail in the aforementioned related applications, has provided further insight into the molecular basis of the disease. See also Rommens, J.M. et al., *Science* 245:1059-1065 (1989); Riordan, J.R. et al., *Science* 245:1066-1073 (1989); Kerem, B.S. et al., *Science* 245:1073-1080 (1989). The gene responsible for CF has been localized to 250,000 bp of genomic DNA based on its
10 location within the genome. This gene encodes a protein of 1480 amino acids called the cystic fibrosis transmembrane conductance regulator (CFTR). Riordan et al., *supra*.

The most compelling evidence thus far to support the role of CFTR in the etiology of CF has been provided by genetic analyses. Kerem et al., *supra*, (1989). Sequence analysis of the CFTR gene of CF chromosomes has revealed a variety of
15 mutations, including nonsense and frameshift mutations. Cutting, G.R. et al., *Nature* 346:366-369 (1990); White, M.B. et al., *Nature* 344:655-667 (1990); Dean, M. et al., *Cell* 61:863-870 (1990); Kerem, B.S. et al., identification of mutations in regions corresponding to the 2 putative nucleotide (ATP) binding folds of the cystic fibrosis
20 gene, *PNAS (USA)* (1990) (in press). However, extensive population studies have indicated that the most common CF mutation is a deletion of the three nucleotides that encode phenylalanine 508 (ΔF_{508}). This deletion is present on 70% of all CF chromosomes, but not on normal chromosomes. Kerem et al., *supra*, (1989); The Cystic Fibrosis Genetic Analysis Consortium (1990).

Results from both physiological and molecular cloning studies have raised the
25 possibility that CFTR is a Cl channel. The defect in Cl channel activation by cAMP-dependent protein kinase (PKA) is present at the single-channel level in cell-free membrane patches and the protein structure predicted from CF gene cloning suggests that CFTR is an integral membrane protein with twelve membrane-spanning domains. Schoumacher, R.A. et al., *Nature* 330:152-754 (1987); Li, M. et al., *Nature* 331:358-360
30 (1988); Riordan et al., *supra*. The identification of CF-associated alterations in other cellular processes such as amiloride-sensitive Na transport and mucin sulfation also supports the view that CFTR may regulate several cellular processes. Boucher et al., *supra*; Boat, T.F. et al; *Arch. Biochem. Biophys.* 177:95-104 (1976).

Although the specific role that CFTR plays in Cl transport remains to be
35 determined, the CFTR protein contains several interesting functional domains including

two nucleotide binding folds, a regulatory region that has many possible sites for phosphorylation, and two hydrophobic regions that probably interact with cell membranes. CFTR shows structural similarity with several members of the "ATP binding cassette" (ABC) superfamily of proteins, including the periplasmic binding proteins of prokaryotes, and the P-glycoprotein associated with multidrug resistance in higher eukaryotes. Riordan et al., *supra*; Hyde, S.C. et al., *Nature* 346:312-365 (1990).

Recent progress in our understanding of the genetic and functional basis of CF has provided a foundation for better defining its molecular pathology as well as 10 developing novel therapies based on somatic gene transfer.

SUMMARY OF THE INVENTION

Gene therapy for cystic fibrosis (CF) comprises the delivery of a gene for functional cystic fibrosis transmembrane conductance regulator (CFTR) to affected epithelial cells. Delivery and expression of a single copy of the normal CFTR gene, as 15 would be expected with a recessive trait such as CF, alleviates the Cl⁻ channel regulation defect present in CF cells. CF caused by a lack of functional CFTR or presence of CFTR function below physiologically-acceptable levels which arises from a defect in the CFTR gene can thus be treated in accordance with the principles of the present invention.

20 The "normal CFTR gene" of the present invention is simply any nucleic acid sequence which codes for functional CFTR. Thus variations in the actual sequence of the gene can be tolerated provided that functional CFTR can be expressed. For example, silent mutations can be introduced to stabilize cloning of the gene. A CFTR gene used in the practice of the present invention can be obtained through 25 conventional methods such as DNA cloning, artificial construction or other means. The 4.6 kb cDNA utilized in the specific examples has all the sequences necessary to encode for a functional CFTR protein, as assayed by the analysis of cAMP-stimulated chloride current.

Gene transfer of the CFTR gene in accordance with the present invention can 30 be accomplished through many means, including transfection using calcium phosphate coprecipitation, fusion of the target cell with liposomes, erythrocyte ghosts or spheroplasts carrying the CFTR gene, plasmid and viral vector-mediated transfer and DNA protein complex-mediated gene transfer.

Presently the delivery vehicle of choice is a recombinant retrovirus capable of 35 infecting human epithelial cells. This is somewhat surprising given the relatively large

siz of th CFTR gene. The recombinant retroviral vector of the invention generally comprises DNA of at l ast the portion of the retroviral genome necessary for infection, and the normal CFTR gene operatively linked thereto. Additionally, the portion of retroviral genome used in construction of the vector can be rendered replication-5 defective to remove any deleterious effects of viral replication on the target cells.

Although any CF-affected epithelial cells such as pancreatic and sweat gland cells can be targeted with the gene transfer methods and vectors of the present invention, because the most severe complications of CF are usually pulmonary, airway epithelial cells are the most desirable targets for gene therapy of the present invention.

10 Moreover, given that airway epithelial cells have been found to be easily infected by recombinant retroviruses, gene transfer in accordance with the present invention to these cells is quite feasible.

CF diagnosis and screening of carriers can also be accomplished through transduction of CFTR defective cells and cell lines. For example, the complementation 15 scheme of the present invention can be use to determine the validity of other putative CF mutations and is also useful as a tool to study the function of CFTR by site-specific mutagenesis or domain switching with other members of this large ABC gene family.

The present invention is thus directed toward gene therapy for cystic fibrosis through delivery and expression of a functional CFTR gene to the cells of a CF patient. 20 Recombinant retroviral vectors as well as other CFTR gene transfer schemes can be used in the practice of the present invention. The present invention further includes both CF epithelial cells and cell lines which carry a normal CFTR gene transduced or transferred therein in accordance with the principles of the invention. CFTR screening and complementation assays for other putative CF mutations are also contemplated 25 within the scope of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A depicts the proviral component of the recombinant retroviral vector PLJ-CFTR of the present invention.

Figure 1B shows the results of gel blot hybridization of Kpn I-restricted DNA 30 using a Neo specific probe (top panel) and Hind III digested DNA using an exon 13 CFTR specific probe (bottom panel).

Figure 2 is an RNA blot analysis of the expression of the retroviral transduced CFTR gene in CFPAC clones using the CFTR exon 13 probe.

Figure 3A is a graph illustrating the effect of forskolin on ¹²⁵I efflux in PLJ and 35 PLJ-CFTR clones over time.

Figure 3B is a graph illustrating the effect of forskolin on ^{125}I efflux in PLJ and PLJ-CFTR clones as compared to basal ^{125}I efflux.

Figure 4A is a whole-cell voltage clamp record of stimulation of inward currents by forskolin in a PLJ-CFTR clone 1.

5 Figure 4B illustrates the failure of cAMP or forskolin in stimulating membrane currents in a PLJ clone 6 cell.

Figure 4C is a graph depicting the instantaneous current-voltage relations of forskolin-induced currents in NaCl, low Cl and Na-free baths.

Figure 5 is the nucleotide sequence of cDNA encoding CFTR together with the 10 deduced amino acid sequence.

Figure 6 depicts a stabilization scheme for a CFTR construct.

Figure 7 is a restriction map of a plasmid-based vector used in the practice of the present invention.

DETAILED DESCRIPTION OF THE 15 PREFERRED EMBODIMENTS OF THE INVENTION

The absence of functional CFTR or CFTR function which is not at physiologically-acceptable levels and which arises from a defect in the CFTR gene is treated through gene transfer of a normal CFTR gene into CFTR defective cells. By

20 "physiologically-acceptable level of CFTR function" is meant a level of CFTR function at which a cell population or patient exhibits the normal physiological effects presence of the normal amounts of CFTR. Examples of insufficiencies in CFTR function include

but are not limited to abnormal Cl channel regulation in epithelial cells, such as that exhibited in cystic fibrosis.

A recombinant viral vector of the present invention comprises DNA of at least 25 a portion of retroviral genome which portion is capable of infecting the target cells and a normal CFTR gene operatively linked to thereto. By "infection" is generally meant the

process by which a virus transfers genetic material to its host or target cell. Preferably the retrovirus used in the construction of a vector of the invention is also rendered replication-defective to remove the effects of viral replication on the target cells. In

30 such cases, the replication-defective viral genome can be packaged by a helper virus in accordance with conventional techniques. Generally any retrovirus meeting the above criteria of infectiousness and capabilities of CFTR gene transfer can be employed in the practice of the present invention may also be desirable. Suitable retroviruses for the practice of this invention include, for example, PLJ, pZip, pWe and

pEM well known to those skilled in the art. Suitable packaging virus lines for replication-defective retr viruses include, for example, Ψ Crip, Ψ Cre and Ψ 2 and Ψ Am.

It will be appreciated that when viral vector schemes are employed for CFTR transfer, the use of attenuated or avirulent viruses may also be desirable. Where 5 applicable in the practice of the invention, amplification of the CFTR gene can also be utilized to enhance the levels of normal CFTR expression.

The genetic material to be recombined with the retroviral vector or transferred through other methods of the invention is preferably provided through conventional cloning methods, i.e. cDNA, through overlapping oligonucleotide sequences or any 10 other suitable method yielding the desired sequence. When used in diagnostic or screening assays, the genetic material is usually provided by cloning of patient DNA or, alternatively, through the use of patient genomic DNA. As stated previously, by normal CFTR gene, is meant any nucleic acid sequence which codes for functional CFTR.

15 The cells targeted for transduction or gene transfer in accordance with the present invention include any cells to which the delivery of the CFTR gene is desired. Generally speaking, the cells are those with the CFTR gene defect, such as CF cells. In the case of CF, the cells targeted are preferably epithelial cells, including pancreatic, sweat gland, liver, intestinal, kidney and even more preferably epithelial airway cells, 20 such as lung cells.

Cells or cell populations can be treated in accordance with the present invention *in vivo* or in *in vitro*. For example, in *in vivo* treatments, CFTR vectors of the present invention can be administered to the patient, preferably in a biologically compatible solution or pharmaceutically acceptable delivery vehicle, by ingestion, 25 injection, inhalation or any number of other methods. The dosages administered will vary from patient to patient and will be determined by the level of enhancement of CFTR function balanced against any risk or deleterious side effects. Monitoring levels of transduction, CFTR expression and/or the presence or levels of normal CFTR will assist in selecting and adjusting the dosages administered. *in vitro* transduction is also 30 contemplated within the present invention. Cell populations with defective CFTR genes can be removed from the patient or otherwise provided, transduced with a normal CFTR gene in accordance with the principles of the invention, then (re)introduced into the patient.

CFTR-defective cell lines, such as transformed CF lines, can also be transduced 35 in accordance with the present invention. Such cell lines are useful, for example, in

complementation assays for evaluating CF mutations to diagnose CF and screen for carriers. For example, patient CFTR cDNA can be transferred into CF cells and the cells screened for complementation, i.e. CFTR function, to confirm or rule out of CF or CFTR gene defects.

5 In the first set of Specific Examples which follow, retrovirus-mediated gene transfer was used to complement the cystic fibrosis (CF) defect in Cl regulation in epithelial cells of a CF patient. Amphotropic retroviruses were used to transduce a functional cystic fibrosis transmembrane conductance regulator (CFTR) cDNA into CFPAC-1, a pancreatic adenocarcinoma cell line derived from a patient with CF. This
10 cell line stably expresses abnormalities in electrolyte transport that are characteristic of the CF defect, i.e. they lack cAMP-stimulated Cl transport. CFPAC-1 cells were exposed to control virus (PLJ) and CFTR-expressing virus (PLJ-CFTR); viral transduced clones were isolated and subjected to molecular and physiologic analysis. Agarose gel blot analysis revealed unarranged proviral sequences in 10 of 10 PLJ clones and
15 9 of 10 PLJ-CFTR clones. RNA analysis detected a viral-derived CFTR transcript in all of the PLJ-CFTR clones. RNA analysis detected a viral-derived CFTR transcript in all of the PLJ-CFTR clones that contained unarranged proviral sequences.

Anion (¹²⁵I) efflux was used to examine PLJ and PLJ-CFTR clones for cAMP and Ca stimulated anion transport. Agents that increase intracellular cAMP stimulated
20 ¹²⁵I efflux in PLJ-CFTR clones but not PLJ clones. Whole-cell patch-clamp performed on two responding clones showed that the anion efflux responses were due to cAMP stimulation of chloride conductance. Calcium ionophore increased ¹²⁵I efflux and chloride currents in all PLJ and PLJ-CFTR clones. These findings indicate that expression of the normal CFTR gene confers cAMP-dependent Cl channel regulation
25 on CF epithelial cells.

The second set of Specific Examples describes gene transfer to airway epithelial cells as well as pancreatic cells, administration of CFTR gene therapy and alternative gene transfer delivery systems, including lipofection and DNA-protein complex-mediated gene transfer.

30 **SPECIFIC EXAMPLES - I**

Recombinant Retroviruses

Early attempts to reconstitute a full length CFTR cDNA from overlapping clones were unsuccessful. The exact cause of these difficulties remains to be defined, but our data indicated that prokaryotic transcription from internal CFTR cDNA sequences may
35 result in the expression of a protein that is toxic to bacteria. The introduction of three

silent mutations (T to C at 930, A to G at 933, and T to C at 936) into a restriction fragment of CFTR that spans exon 6b completely ablated this toxic effect, potentially by interfering with the cryptic prokaryotic promoter, and enabled the reconstruction of 4.6 kb of contiguous CFTR cDNA sequence. The nucleotide sequence of this 5 reconstructed cDNA was re-determined and found identical to that published previously with the exception of the three silent mutations noted above. See Riordan et al., *supra*.

Sequence Listing set forth before the Claims illustrates the nucleotide sequence of cDNA encoding CF transmembrane conductance regulator along with the deduced amino acid sequence. The DNA sequencing was performed by the dideoxy chain 10 termination method with 35 S-labeled nucleotides or by the Dupont Genesis 2000 automatic DNA sequencer. Numbers on the right of the columns in Figure 5 indicate base positions. The first base position corresponds to the first nucleotide in the 5' extension clone PA3-5, which is one nucleotide longer than TB2-7. The 3' end and the noncoding sequence are also shown in the Figure (nucleotides 4561 to 6129 plus 15 the poly(A)⁺ tail). The arrows shown indicate the position of transcription initiation site by primer extension analysis. As shown abbreviated in the Figure, nucleotide 6129 is followed by a poly(A) tract. The positions of exon junctions are between the following base positions: 185-186; 296-297; 405-406; 621-622; 711-712; 1001-1002; 1248-1249; 1341-1342; 1523-1524; 1716-1717; 1811-1812; 1898-1899; 2621-2622; 20 2789-2790; 3040-3041; 3120-3121; 3499-3500; 3599-3600; 3849-3850; 4005-4006; 4095-4096; 4268-4269; and 4374-4375.

Potential membrane-spanning segments were ascertained with the use of the algorithm of Eisenberg, et al., *J. Mol. Biol.* 179:125 (1984) and are underlined under the nucleic acid designations in the Figure. Amino acids comprising putative ATP-binding 25 folds are underlined under the amino acid designations in the Figure. Possible sites of phosphorylation by protein kinases A or C are indicated by o and *, respectively, and + designates glycosylation sites. The open triangle indicates the position at which 3 bp are deleted in CF. Abbreviations for the amino acid residues used in Figure 5 are: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; Ile; K, Lys; L, Leu; M, Met; 30 N, Asn; P, Pro; Q, Gin; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Try.

The modified CFTR cDNA was cloned into the retroviral vector PLJ previously described by Korman, A.J. et al., *PNAS (USA)* 84:2150-2154 (1987). The proviral component of this recombinant vector, called PLJ-CFTR, is depicted in Figure 1A. Important structural components of the vector illustrated in the Figure include the long- 35 terminal repeat sequences (LTR), CFTR cDNA, sequences from the origin of SV40, the

gen that confers resistance to G418 (Neo), and the origin of replication for pBR322 (pBR). Transcription from the 5'LTR produces the 8.5 kb genomic transcript that is responsible for viral passage and CFTR expression. Transcription from the SV40 sequences leads to the formation of the second transcriptional unit that expresses a 5 Neo-selectable marker. Sites of transcriptional initiation are indicated in Figure 1A with arrows at the 5' LTR and internal SV40 sequences. Recognition sites for restriction endonucleases Kpn I and Hind III are also indicated. Probes specific for the CFTR gene (exon 13) and the Neo gene that were used in DNA and RNA blot analysis are indicated below the vector.

10 Transfection of PLJ and PLJ-CFTR vectors into the virus packaging cell line Ψ Crip led to the transient production of replication-defective virus. Limiting dilutions of virus stocks were used to infect CFPAC-1 cells which were subsequently cultured in the presence of G418 in order to select for transduced clones. Transiently produced PLJ-CFTR virus stocks had a lower titer (50-100 fold) than those produced with PLJ 15 vector. Ten individual clones of cells were isolated from infections performed with each type of virus (named PLJ clones 1 through 10 and PLJ-CFTR clones 1 through 10) and subjected to molecular and physiologic analysis.

Transduced Clones Express Retroviral CFTR Sequences

20 Retrovirally transduced clones of CFPAC-1 cells were analyzed for proviral sequences as described for other cells types by Wilson, J.M. et al., *PNAS (USA)* 85: 4421-4425 (1988) and Wilson, J.M. et al., *Science* 248:1413-1416 (1990). CFPAC-1 cells were infected with PLJ or PLJ-CFTR virus and selected in the presence of G418 in order to isolate individual clones. High molecular weight DNA was isolated from each clone and analyzed by the method of gel blot hybridization as shown in Figure 25 1B. In the top panel of Figure 1B, DNA was digested with Kpn I and the filter was hybridized to a Neo specific probe, whereas in the bottom panel, DNA was digested with Hind III and the filter was hybridized to the exon 13 CFTR specific probe. The 4.3 kb band in all lanes arises from the endogenous CFTR gene. Samples include: CFPAC-1 DNA (10 μ g); lane "1 copy" - CFPAC-1 DNA (10 μ g) and lanes "PLJ-CFTR 30 1 through 10" - DNA (10 μ g) from PLJ-CFTR clones 1 through 10. Along the right border of the figure, molecular size standards in kilobases are indicated.

35 Digestion of high molecular weight DNA with restriction enzyme Kpn I, which has unique sites in the vector LTRs, released all integrated forms of the PLJ-CFTR provirus as a common 8.5 kb fragment. As indicated in the top panel of Figure 1B, gel blot hybridization of Kpn I-restricted DNA revealed unarranged proviral sequences

with the expected abundance of one copy per cell in 10/10 PLJ clones and 9/10 PLJ-CFTR clones. Hybridization of the filter with a Neo-specific probe detected a markedly rearranged provirus in PLJ-CFTR clone 2; this virus apparently deleted a major part of the CFTR cDNA (data not shown).

5 The results of gel blot hybridization analysis to study the complexity and uniqueness of each putative PLJ-CFTR clone is shown in the bottom panel of Figure 1B. High molecular weight DNA was isolated and digested with Hind III, a restriction enzyme with two internal sites in PLJ-CFTR, and analyzed with the exon 13 CFTR specific probe. As illustrated in the bottom panel of Figure 1B, this analysis
10 demonstrated a single unique integration site in 9/10 PLJ-CFTR clones. The CFTR specific probe failed to detect the provirus in DNA from PLJ-CFTR clone 2 because of the apparent deletion described above.

Expression of the retroviral transduced CFTR gene was studied by RNA blot analysis of CFPAC-1 clones using the CFTR exon 13 probe and is shown in Figure 2.
15 Clones of retrovirus transduced CFPAC-1 cells were isolated and analyzed for the presence of CFTR transcripts. Total cellular RNA was harvested from individual clones and subjected to RNA blot analysis using the exon 13 CFTR probe to hybridize with the filter as shown in the top panel of Figure 2. In the bottom panel of Figure 2, the filter was stripped and rehybridized with a probe derived from human γ -actin cDNA in
20 order to control for variation in sample loading. RNA samples (10 μ g) were derived from the following cells: lanes "T84" - duplicate samples from the colonic tumor cell line T84; lane "CFPAC-1" - nontransduced CFPAC-1 cells; lane "PLJ 6" - CFPAC-1 clone #6 from the PLJ infection; and lanes "PLJ-CFTR 1 to 10" - CFPAC-1 clones #1 through #10 from the PLJ-CFTR infection. Along the left border of the figure,
25 molecular size standards in kilobases are indicated.

As illustrated in Figure 2, total cellular RNA from the previously described human colon tumor cell line, T84, demonstrated high levels of the endogenous CFTR transcript. No CFTR transcript was detected by Northern analysis in mock infected CFPAC-1 cells or PLJ clones 1 though 10 CFTR RNA can be detected in CFPAC-1 by
30 RNA-PCR. A viral directed CFTR transcript of the expected size (i.e., 8.5 kb) was detected in 9/10 PLJ-CFTR clones; the CFTR probe failed to detect a transcript in RNA from the clone that contains the deleted provirus (PLJ-CFTR clone 2).

Transduced Clones Show Forskolin Stimulation of Anion Transport

Isotopic anion (^{125}I) effluxes were measured to screen the PLJ and PLJ-CFTR
35 clones for cAMP- and Ca-stimulated anion transport. The efflux assay, described by

Venglarik, C.J. et al., *Am. J. Physiol.* 259:C358-C364, (1990) provides a qualitative estimate of agonist-stimulated Cl conductance pathways in Cl⁻ secreting epithelia, as judged from the inhibitory effects of Cl channel blockers and depolarizing membrane potentials on ¹²⁵I efflux. Figure 3A shows the time-course of the ¹²⁵I efflux rate constant (r) in two clones, PLJ 6 and PLJ-CFTR 6, with and without the addition of forskolin, an agent which stimulates adenylate cyclase. 10 μM of forskolin was added at the time indicated in Figure 3A. Following a basal efflux period in the absence of agonist (not shown), forskolin increased ¹²⁵I efflux rate from PLJ-CFTR clone 6 from 0.32 to 0.70 min⁻¹; PLJ 6 did not respond. r values obtained before forskolin addition and during the peak of the forskolin response provided an estimate of the relative stimulation of ¹²⁵I efflux (i.e. $r_{\text{forsk}}/r_{\text{basal}}$). In the responding PLJ-CFTR clones, the peak forskolin effect on anion efflux was observed during the first three flux periods following forskolin addition (15-45 sec). The mean +/-SEM was n=9 for all clones except PLJ5 where n=7.

15 Data derived from twenty clones is illustrated in Figure 3B. The r values were taken before and after the addition of forskolin. For PLJ-CFTR clone 2 the same scaling applies below 1.0. The values are mean +/-SEM; n=9 for all clones except PLJ5 where n=7. As illustrated in Figure 3B, seven of ten PLJ-CFTR clones showed significant increases in ¹²⁵I efflux in response to forskolin, whereas none (0/10) of the 20 control PLJ clones responded to forskolin. The parent cell line, CFPAC-1, also shows no response to forskolin or cAMP analogues as described by Schoumacher, R.A. et al., *PNAS (USA)* 87:4012-4016 (1990). PLJ-CFTR clone 2 showed a major deletion in its CFTR cDNA by gel blot hybridization as shown in Figure 1B, accounting for the failure of forskolin to stimulate ¹²⁵I efflux. In the seven responding PLJ-CFTR clones, 25 the relative stimulation of anion efflux by forskolin ranged from 1.8 to 2.8-fold. This compares well with the 3.5-fold stimulation of efflux reported recently for the colonic tumor cell line T84 by Venglarik, *supra*. Our results indicate that expression of CFTR cDNA endows CFPAC-1 cells with cAMP-responsive anion efflux.

The correlation between forskolin responsiveness of the PLJ-CFTR clones and 30 their CFTR mRNA levels was not striking as illustrated by a comparison of Figures 2 and 3B. Three of the best responders in efflux assay showed high mRNA levels (i.e., PLJ-CFTR clones 1, 6 and 10). In other instances, however, the correlation was not as good. For example, clones 7 and 8 showed approximately a 2-fold response to forskolin but had relatively low mRNA levels, and clones 3 and 9 showed a low 35 forskolin response, despite the presence of readily detectable CFTR mRNA.

Addition of the Ca ionophore, ionomycin, increased ^{125}I efflux in all control and CFTR clones. Values of ^{125}I basal averaged $14+/-2$ in PLJ and $14+/-1$ in PLJ-CFTR ($n=20$) in each group; no significant differences were detected between individual clones. The extent of response of PLJ clones to ionomycin is similar to that observed previously in wild-type CFPAC-1 cells by Schoumacher et al., *supra* (1990), and is about three times the response of T84 cells observed by Venglarik et al., *supra*. The ability of Ca ionophores and Ca-mediated agonists to stimulate Cl⁻ secretion has been reported for airway and sweat gland cells derived from both normal individuals and CF patients. See Sato, K. et al., *J. Clin. Invest.* 73:1763-1771 (1984); Frizzell et al., *supra* (1986); Willumsen, N.J. et al., *Am. J. Physiol.* 256:C226-C233 (1989). The presence of this response in CF cells indicates that CFTR is not required for Ca-mediated Cl⁻ transport stimulation. The lack of significant differences in the extent of Ca stimulation in PLJ and PLJ-CFTR clones suggest that CFTR does not modulate the activity of Ca-mediated regulatory pathways that govern Cl⁻ secretion.

15 **Clones Transduced with the CFTR Retrovirus Show cAMP-Induced Cl⁻ Currents**

Whole-cell patch-clamp recordings were used to determine whether the cAMP-induced increase in anion efflux in PLJ-CFTR clones of Figure 3 was due to stimulation of Cl⁻ conductance pathways as described by Cliff, W.H. et al., *PNAS (USA)* 87:4956-4960 (1990). A typical response of PLJ-CFTR clone 1 is shown in Figure 4A which illustrates stimulation of inward currents by 5 μM forskolin. Membrane voltage was held at -10 mV and pulsed to 0 and -84 mV. The gap in the record represents time (6 min) during which bath solution substitutions were performed to determine ion selectivity of the forskolin-induced current. The pulse protocols for determining the I-V relations were run at the times indicated in the Figure. Chloride currents were measured as the inward current produced by voltage pulses to -84 mV. Similar increases in inward current were observed in 11 of 13 cells from PLJ-CFTR clones 1, 6, and 10 in which addition of forskolin (5 μM) or cAMP (200 to 800 μM) increased inward currents from $220+/-68$ pA to $1690+/-495$ pA in responding cells. The magnitude of this response compares favorably with that observed in T84 cells by Cliff et al., *supra*. As shown in Figure 4B, cAMP (400 μM) or forskolin (5 μM) failed to stimulate membrane currents in cells from the control clone, PLJ 6 ($n=6$). The membrane voltage was held at -20 mV and pulsed to 0 mV and -84 mV. Similar results were obtained in 5 PLJ clone 6 cells. As observed from the ^{125}I efflux determinations, ionomycin (2 μM) increased inward currents in both PLJ ($n=4$) and PLJ-CFTR ($n=3$) clones.

As shown in Figure 4C, instantaneous current-voltage (I-V) relations of the forskolin-stimulated current in a NaCl bath, a low Cl bath, and a Na-free bath were obtained from PLJ-CFTR clone 1. Forskolin-induced currents were obtained by digital subtraction of currents before and after stimulation. The values shown in Figure 4C 5 were recorded 6 msec after the initiation of voltage pulses. These data were obtained from the PLJ-CFTR clone 6 cell record shown in Figure 4A during the 6 min. recording gap.

As illustrated in Figure 4C, the I-V relation of the stimulated current appeared to be linear, as observed in T84 cells by Cliff et al., *supra*. Currents were determined 10 using equal bath and pipette Cl concentrations reversed near the Cl equilibrium potential of 0 mV. Reducing bath Cl to 6 mM (glutamate replacement) decreased the outward currents and shifted the reversal potential for current flow to +66 mV, a value close to the Cl equilibrium potential (+80 mV) for this outwardly-directed Cl gradient. Replacement of bath Na by N-methyl-D-glucamine (NMDG) did not significantly alter 15 the I-V relation. These findings indicate that the forskolin-stimulated current is Cl-selective, and that the stimulation of anion efflux in PLJ-CFTR clones is due to activation of Cl conductance pathways.

EXPERIMENTAL PROCEDURES

The following experimental procedures were employed in the Specific Examples 20 set forth above:

CFPAC-1 cells were maintained in culture as described previously by Schoumacher et al., *supra* (1990); cells used for retroviral infection were at passage 72. Infection populations of CFPAC-1 cells were selected in medium containing G418 (1 mg/ml) in order to isolate individual clones. Transduced CFPAC-1 cells were 25 removed from selection soon after they were expanded as clones. This was not associated with an apparent loss of proviral sequences or proviral expression. The amphotropic packaging cell line Ψ Crip, was maintained in Dulbecco's modified Eagle's medium supplemented with 10% calf serum and penicillin/streptomycin as described by Danos, O. et al., *PNAS (USA)* 85:5460-6464 (1988).

30 **Construction of CFTR cDNA**

The cDNA was constructed by joining the overlapping clones 10-1, T16-1 and T16-4.5 as described by Riordan et al., *supra*. 10-1 and T16-1 were ligated at the unique Nru I site in exon 4 and the resultant construct, spanning exons 1 through 13, joined to T16-4.5. This was done by inserting a Sac I-Eco RI partial digestion product 35 of T16-4.5, extending from exon 13 to exon 24, into the respective sites of the 5' 13-

exon construct. These manipulations generated a 4.5 kb clone containing the entire coding sequence as previously described by Riordan et al., *supra*. It was observed that most clones generated from these construction attempts were grossly rearranged. Upon sequencing of an apparently intact construct, a 57 bp deletion was identified in 5 exon 6b occurring between the two copies of a 13 bp direct repeat. On inspection, this interval was noted to contain a consensus prokaryotic promoter sequence. In an attempt to disrupt the repeat, three single nucleotide alterations were made by *in vitro* mutagenesis. The introduced changes which do not alter the CFTR translation product and result in a stable construct, include substitution of C for T at position 930, G for 10 A at 933, and C for T at position 936. The modified reconstructed CFTR plasmid is called CFTR 4.6.

The above described changes were accomplished by synthesis of an oligonucleotide which matched the normal sequence except for the presence of G at 933 and C at 936. The antisense strand of this segment of the CFTR cDNA was 15 cloned into single-stranded M13 phage, and mutagenized with the oligonucleotide using standard techniques as described by Smith, M., (1989) *Annu. Rev. Genet.* 19:423 (1985); Sanbrook, J., et al.: *Molecular cloning. A Laboratory Manual*, 2nd ed., Cold Spring Harbor Press, 15.51-15.80 (1989). The resulting clone, shown in Figure 6, was sequenced and found to have an additional unexpected base change at position 930, 20 which is also in a silent nucleotide position not altering the encoded protein.

It will also be appreciated that other methods to stabilize the full-length CFTR cDNA can be used in the practice of the invention. Any alteration in the fortuitous *E. coli* promoter in exon 6b, as shown in Figure 6, which renders it non-functional while preserving the correct amino acid coding sequence for CFTR will accomplish this same 25 goal. For example, mutagenesis of the CATACT sequence underlined in Figure 6 can be accomplished in several ways which will not alter the amino acid sequence (e.g. CGTATT), but will inactivate the sequence as a prokaryotic promoter, rendering it stable in the usual cloning vectors.

Retroviral Vectors and Recombinant Retroviruses

30 Digestion of the modified CFTR plasmid with Sac I released the modified CFTR cDNA on a 4.6 kb restriction fragment. The Sac I sites were converted to Bcl I sites with oligonucleotides and the linker fragment was cloned into the Bam I site of the retroviral vector PLJ previously described by Korman et al., *supra*. This recombinant vector, called PLJ-CFTR, is presented in Figure 1A. Retroviral vector PLJ and PLJ- 35 CFTR were transfected into the amphotropic packaging cell line Ψ Crip as described.

Tissue culture media was removed from plates containing the transfected packaging cells 24 hours later in order to harvest the transiently produced amphotropic virus.

CFPAC-1 cells, passaged 1:5 onto 10 cm² plates, were exposed to viral supernatants supplemented with polybrene (4 µg/ml) for 12 to 16 hours. When the 5 cells reached confluence, they were passaged 1:10 into medium containing G418 (1 mg/ml). Clones of cells were isolated, expanded, and cryopreserved.

DNA and RNA Analysis of CFPAC-1 Clones

High molecular weight DNA was isolated from CFPAC-1 cells as described and analyzed by gel blot hybridization as described by Wilson et al., *supra* (1988). Total 10 cellular RNA was purified and subjected to RNA blot analysis of Wilson et al., *supra* (1988). Filters were hybridized with a variety of DNA probes that were labeled to a high specific activity using the random priming method of Feinberg, A.P. et al., *Anal. Biochem.* 132:6-13 (1983). These probes include: 1) Exon 13 of CFTR isolated following PCR amplification of cloned cDNA using oligonucleotides that flank the 15 borders of this exon, (NT 1900 to 2611); 2) Neo-specific sequences on a 960 base pair Hind III to Nco I fragment of pSV2Neo, and 3) human γ actin cDNA.

Anion Efflux Measurements

Radioisotopic anion efflux was determined as described by Venglarik et al., *supra*. Briefly, cell monolayers were preloaded with ¹²⁵I for 30 min; after two washes, 20 efflux was monitored at 15 sec intervals using a sample-replace procedure. At the end of the experiment, tracer remaining in the cell monolayer was extracted with 0.1 N HPO₃. The efflux rate constant (r) for each sampling interval was calculated as follows: $r = [\ln (R_1) - \ln (R_2)]/(t_1 - t_2)$, where R₁ and R₂ are the percent of loaded ¹²⁵I remaining in the monolayer at times (t) 1 and 2. Forskolin or ionomycin were added 25 after the fifth 15-sec sampling interval. The degree of agonist stimulation is expressed as $\gamma_{\text{agonist}}/\gamma_{\text{basal}}$ where γ_{agonist} is the maximal value observed in the presence of agonist and γ_{basal} is taken from flux interval immediately prior to agonist addition.

Most of the extracellular ¹²⁵I washout occurs during the initial 60 sec of sampling as set forth by Venglarik et al., *supra*; this period was ignored in the rate 30 constant calculations. However, a small residual efflux from the extracellular space after 60 sec leads to a slight underestimate of the agonist response because the extracellular compartment washes out faster than the cellular compartment. Therefore, when there is no efflux response to forskolin, r determined immediately after forskolin addition is slightly less than that measured before forskolin is added. This accounts

for the finding that $\gamma_{\text{forsk}}/\gamma_{\text{basal}}$ is between 0.9 and 1.0 in the PLJ clones shown in Figure 3B.

Whole-Cell Current Recordings

Macroscopic currents were recorded during whole-cell patch-clamp by methods previously described by Cliff et al., *supra*. Recordings were made at 37°C with the following solutions (mM); bath: 115 NaCl, 40 N-methyl-D-glucamine (NMDG)-glutamate, 5 K-glutamate, 2 MgCl₂, 1 CaCl₂, 10 HEPES (pH 7.2); pipette: 115 KCl, 35 NMDG-glutamate, 0.25 EGTA, 0.09 CaCl₂ (100 nM free Ca), 2 MgCl₂, 2 Na₂ATP, 0.20 Na₂GTP, 10 HEPES (pH 7.2). Membrane potentials were clamped alternately for 500 msec duration at three voltages, two of which were chosen to equal the equilibrium potentials for Cl (0 mV) and K (-84 mV). This permits the Cl and K currents to be monitored during agonist responses as described by Cliff et al., *supra*. Pulsing was interrupted to determine current-voltage relations by stepping the clamp voltage between +/- 100 mV at 20 mV increments as shown in Figure 4C.

15 SPECIFIC EXAMPLES - II

Retrovirus-Mediated Transduction of Pancreatic and Pulmonary Epithelial Cells

Retrovirus-mediated gene transduction into various epithelial cells was optimized using a replication defective retrovirus that expresses the β -galactosidase gene from *E. coli*. This was used because expression of viral directed β -galactosidase can be detected *in situ* using cytochemical reaction that stains the transduced cell blue. The amphotropic virus producer cell line made from the β -galactosidase expressing BAG vector, which has been described previously, was used as a source of virus. This virus producing cell line is called BAG5. The supernatant over a confluent plate of BAG5 cells was harvested, filtered, and used to infect various epithelial cells as described below.

Pancreatic Epithelial Cell Line

CFPAC-1 is a cell line derived from an adenocarcinoma of a patient with CF which expresses the cellular defect characteristic of CF (i.e. chloride channels are not activated in the presence of cAMP agonists). CFPAC-1 cells were split at various dilutions (1:2, 1:5, 1:10, and 1:20) and 24 hours later exposed to fresh virus supernatants that had been supplemented with polybrene (4 μ g/ml). Twelve hours later the virus was replaced with fresh medium. When confluent, the cells were analyzed for the expression of viral directed β -galactosidase as described. Optimal infection efficiency was obtained with CFPAC-1 cells that were split 1 to 5 the day before infection. Under optimal conditions, a single exposure to virus led to stable

transduction of the β -galactosidase gene into 30-40% of the cells. Expression of β -galactosidase has been stable in cultured cells for over 2 months. Attempts to reinfect CFPAC-1 cells on subsequent days led to little augmentation of infection efficiency.

Airway Epithelial Cells

5 As discussed previously, airway epithelial cells are the most desirable targets for gene transfer because the pulmonary complications of CF are usually its most morbid and life-limiting. Taussig, *supra* (1984). Since airway epithelial cells are easily infected with recombinant retroviruses, the gene transfer approaches described in the preceding and following examples will also be useful for gene therapies directed to
10 airway epithelial cells such as those of the lung.

An epithelial cell line derived from an airway of a patient with CF was used as a potential target for retrovirus-mediated gene transfer. These cells had been described previously and have been called T43 cells. Freshly harvested BAG5 virus was supplemented with polybrene and exposed to T43 cells that had been split 1:5, 15 24 hours previously. Cells were exposed to virus for 12-18 hours and allowed to grow to confluence before being analyzed for viral directed β -galactosidase expression using the previously described cytochemical assay. Under optimal conditions, greater than 25% of CFPAC cells were stably transduced with the β -galactosidase gene after a single exposure to virus.

20 **Direct Delivery of CFTR Expressing Vectors to the Airway Epithelial Cells**

One approach to the use of recombinant retroviruses and the treatment of CF is to introduce a functional CFTR gene into epithelial cells *in vivo* by directly delivering retroviruses into the airway. Several approaches can be taken for the direct delivery of retroviruses. The more invasive approach would be to intubate the patient and 25 lavage the airway with concentrated solutions of CFTR expressing retroviruses. Stable retroviral expression requires that the provirus integrates into chromosomal DNA. This occurs most efficiently if the recipient cells are dividing. It may be necessary to stimulate regeneration of the epithelial soon after exposure to virus. This could be accomplished with mechanical or chemical irritation of the airway.

30 The less morbid approach would be to deliver the normal CFTR gene to airway epithelial cells *in vivo* by a nebulized preparation that can be inhaled. Many different pharmacologic agents are efficiently delivered to a large surface of the airway by nebulized treatments. It is possible that the beneficial effect achieved by this method may be transient. It may, therefore, be necessary to give repeated doses of the drug.

35 The gene delivery system used for direct gene introduction may not have to be viral

based. Direct inhalation of DNA protein complexes or DNA expression vectors in liposomes may be a safer and more effective gene delivery system than retroviruses.

Transplantation of Genetically Modified Airway Epithelial Cells

This approach to somatic gene therapy of CF is similar in concept to bone marrow directed gene therapy. We would propose to isolate airway epithelial cells from the CF patient, establish cultures of the cells, use recombinant retroviruses described in this invention to stably correct the defect in the cells, and transplant the genetically modified cells into the patient so they can repopulate the airway. In order to achieve efficient repopulation in the airway with genetically modified cells, it may be necessary to perturb the integrity of the endogenous epithelial lining through mechanical or chemical irritation.

Alternative Gene Transfer Delivery Systems

Other gene delivery systems for genetic correction of CF defects also fall within the scope of the present invention. For these experiments plasmid-based DNA vectors will be used. An example of such a vector is BA-CFTR BQ presented in Figure 7. This is a simple 7762 bp transfection-based vector in which transcription is initiated from actin flanking systems and terminated from heterologous 3' polyadenylation β sequences.

The vector was constructed in the following manner. The backbone contained sequences from PC18 (nucleotide 6928 to 4553) the 5' flanking region of the chicken β actin gene (nucleotide 6928 to 7754) and 3' flanking sequences of Bovine growth hormone polyadenylation signal (nucleotide 4827 to 4553). The full length CFTR sequences spanning the entire coding region, and containing the three nucleotide changes discussed earlier, were removed from the vector CFTR on a Sac I to Sal I fragment, and cloned into the vector backbone described above.

It will be appreciated by those skilled in the art that this vector could be used in several gene delivery systems.

Lipofection

The previously described procedure is based on the encapsidation of DNA liposomes. When cells are incubated with liposomes, they take up the DNA and express it. We proposed to dilute DNA of an expression vector and lipid (DOTMA) to 1.5 ml in Hepes buffered saline and mix these constituents to form lipid-DNA complexes. Liposomes could then be used to transfect airway cells *in vivo* by lavaging an intubated patient with liposome containing solution or by administering the liposomes by inhalation.

DNA-Protein Complexes

An alternative approach to targeted gene delivery is through the formation of a DNA protein complex. This type of gene transfer substrate is constructed in the following manner. A polypeptide ligand for a receptor on a respiratory epithelial cell 5 is conjugated to polylysine with ethylidene diamino carbodiimide as described. This protein conjugate is complexed to DNA of a transfection vector by mixing equal mass quantities of protein conjugate and DNA in 0.25 molar sodium chloride. The DNA/protein complex is taken up by respiratory airway cells and the gene is expressed. This could be used to directly deliver the CFTR gene to airway epithelial 10 cells *in vivo* using the approaches described for liposomes.

It is apparent that many modifications and variations of this invention as set forth as may be made without departing from the spirit and scope thereof. The specific embodiments described herein are given by way of example only and the invention is limited only by the terms of the appended claims.

SEQUENCE LISTING

↓ ↓

AAT TGG AAG CAA ATG ACA TCA CAG CAG GTC AGA GAA AAA GGG TTG 45
 AGC GGC AGG CAC CCA GAG TAG TAG GTC TTT GGC ATT AGG AGC TTG 90
 AGC CCA GAC GGC CCT AGC AGG GAC CCC AGC GCC CGA GAG ACC ATG 135
 M

CAG AGG TCG CCT CTG GAA AAG GCC AGC GTT GTC TCC AAA CTT TTT 180
 Q R S P L E K A S V V S K L F

TTC AGC TGG ACC AGA CCA ATT TTG AGG AAA GGA TAC AGA CAG CGC 225
 F S W T R P I L R K G Y R Q R

CTG GAA TTG TCA GAC ATA TAC CAA ATC CCT TCT GTT GAT TCT GCT 270
 L E L S D I Y Q I P S V D S A

*

GAC AAT CTA TCT GAA AAA TTG GAA AGA GAA TGG GAT AGA GAG CTG 315
 D N L S E K L E R E W D R E L

*

GCT TCA AAG AAA AAT CCT AAA CTC ATT AAT GCC CTT CGG CGA TGT 360
 A S K K N P K L I N A L R R C

TTT TTC TGG AGA TTT ATG TTC TAT GGA ATC TTT TTA TAT TTA GGG 405
 F F W R F M F Y G I F L Y L G

GAA GTC ACC AAA GCA GTA CAG CCT CTC TTA CTG GGA AGA ATC ATA 450
 E V T K A V Q P L L G R I I

GCT TCC TAT GAC CCG GAT AAC AAG GAG GAA CGC TCT ATC GCG ATT 495
 A S Y D P D N K E E R S I A I

TAT CTA GGC ATA GGC TTA TGC CTT CTC TTT ATT GTG AGG ACA CTG 540
 Y L G I G L C L L F I V R T L

CTC CTA CAC CCA GCC ATT TTT GGC CTT CAT CAC ATT GGA ATG CAG 585
L L H P A I F G L H H I G M Q

*

ATG AGA ATA GCT ATG TTT AGT TTG ATT TAT AAG AAG ACT TTA AAG 630
 M R I A M F S L I Y K K T L K

*

CTG TCA AGC CGT GTT CTA GAT AAA ATA AGT ATT GGA CAA CTT GTT 675
 L S S R V L D K I S I G Q L V

AGT CTC CTT TCC AAC AAC CTG AAC AAA TTT GAT GAA GGA CTT GCA 720
 S L L S N N L N K F D E G L A

TTG GCA CAT TTC GTG TGG ATC GCT CCT TTG CAA GTG GCA CTC CTC	765
<u>L A H F V W I A P L Q V A L L</u>	
ATG GGG CTA ATC TGG GAG TTG TTA CAG GCG TCT GCC TTC TGT GGA	810
<u>M G L I W E L L Q A S A F C G</u>	
CTT GGT TTC CTG ATA GTC CTT GCC CTT TTT CAG GCT GGG CTA GGG	855
<u>L G F L I V L A L F Q A G L G</u>	
*	
AGA ATG ATG ATG AAG TAC AGA GAT CAG AGA GCT GGG AAG ATC AGT	900
<u>R M M M K Y R D Q R A G K I S</u>	
GAA AGA CTT GTG ATT ACC TCA GAA ATG ATT GAA AAT ATC CAA TCT	945
<u>E R L V I T S E M I E N I Q S</u>	
GTT AAG GCA TAC TGC TGG GAA GAA GCA ATG GAA AAA ATG ATT GAA	990
<u>V K A Y C W E E A M E K M I E</u>	
*	
AAC TTA AGA CAA ACA GAA CTG AAA CTG ACT CGG AAG GCA GCC TAT	1035
<u>N L R Q T E L K L T R K A A Y</u>	
G TG AGA TAC TTC AAT AGC <u>TCA GCC TTC TTC TCA GGG TTC TTT</u>	1080
<u>V R Y F N S S A F F F S G F F</u>	
G TG GTG TTT TTA TCT GTG CTT CCC TAT GCA CTA ATC AAA <u>GGA ATC</u>	1125
<u>V V F L S V L P Y A L I K G I</u>	
ATC CTC CGG AAA ATA TTC ACC ACC ATC TCA TTC TGC ATT GTT CTG	1170
<u>I L R K I F T T I S F C I V L</u>	
G CG ATG GCG GTC ACT CGG CAA TTT CCC TGG GCT GTA CAA ACA TGG	1215
<u>R M A V T R Q F P W A V Q T W</u>	
TAT GAC TCT CTT GGA GCA ATA AAC AAA ATA CAG GAT TTC TTA CAA	1260
<u>Y D S L G A I N K I Q D F L Q</u>	
AAG CAA GAA TAT AAG ACA TTG GAA TAT AAC TTA ACG ACT ACA GAA	1305
<u>K Q E Y K T L E Y N L T T T E</u>	
GTA GTG ATG GAG AAT GTA ACA GCC TTC TGG GAG GAG GGA TTT GGG	1350
<u>V V M E N V T A F W E E G F G</u>	
GAA TTA TTT GAG AAA GCA AAA CAA AAC AAT AAC AAT AGA AAA ACT	1395
<u>E L F E K A K Q N N N N R K T</u>	
o	
TCT AAT GGT GAT GAC AGC CTC TTC AGT AAT TTC TCA CTT CTT	1440
<u>S N G D D S L F F S N F S L L</u>	
GGT ACT CCT GTC CTG AAA GAT ATT AAT TTC AAG ATA GAA AGA GGA	1485
<u>G T P V L K D I N F K I E R G</u>	

CAG TTG TTG GCG GTT GCT GGA TCC ACT GGA GCA GGC AAG ACT TCA	1530
<u>O L L A V A G S T G A G K T S</u>	
CTT CTA ATG ATG ATT ATG GGA GAA CTG GAG CCT TCA GAG GGT AAA	1575
<u>L L M M I M G E L E P S E G K</u>	
*	
ATT AAG CAC AGT GGA AGA ATT TCA TTC TGT TCT CAG TTT TCC TGG	1620
<u>I K H S G R I S F C S O F S W</u>	
*	
ATT ATG CCT GGC ACC ATT AAA GAA AAT ATC ATC ^{ATC} TTT GGT GTT TCC	1665
<u>I M P G T I K E N I I F G V S</u>	
TAT GAT GAA TAT AGA TAC AGA AGC GTC ATC AAA GCA TGC CAA CTA	1710
<u>Y D E Y R Y R S V I K A C O L</u>	
GAA GAG GAC ATC TCC AAG TTT GCA GAG AAA GAC AAT ATA GTT CTT	1755
<u>E E D I S K F A E K D N I V L</u>	
GGA GAA GGT GGA ATC ACA CTG AGT GGA GGT CAA CGA GCA AGA ATT	1800
<u>G E G G I T L S G G Q R A R I</u>	
TCT TTA GCA AGA GCA GTA TAC AAA GAT GCT GAT TTG TAT TTA TTA	1845
<u>S L A R A V Y K D A D L Y L L</u>	
*	
GAC TCT CCT TTT GGA TAC CTA GAT GTT TTA ACA GAA AAA GAA ATA	1890
<u>D S P F G Y L D V L T E K E I</u>	
TTT GAA AGC TGT GTC TGT AAA CTG ATG GCT AAC AAA ACT AGG ATT	1935
<u>F E S C V C K L M A N K T R I</u>	
TTG GTC ACT TCT AAA ATG GAA CAT TTA AAG AAA GCT GAC AAA ATA	1980
<u>L V T S K M E H L K K A D K I</u>	
*	
TTA ATT TTG AAT GAA GGT AGC AGC TAT TTT TAT GGG ACA TTT TCA	2025
<u>L I L N E G S S Y F Y G T F S</u>	
GAA CTC CAA AAT CTA CAG CCA GAC TTT AGC ⁰ TCA AAA CTC ATG GGA	2070
<u>E L Q N L Q P D F S S K L M G</u>	
TGT GAT TCT TTC GAC CAA TTT AGT GCA GAA AGA AGA AAT TCA ATC	2115
<u>C D S F D Q F S A E R R N S I</u>	
CTA ACT GAG ACC TTA CAC CGT TTC TCA TTA GAA GGA GAT GCT CCT	2160
<u>L T E T L H R F S L E G D A P</u>	
*	
GTC TCC TGG ACA GAA ACA AAA AAA CAA TCT TTT AAA CAG ACT GGA	2205
<u>V S W T E T K K Q S F K Q T G</u>	

GAG TTT GGG GAA AAA AGG AAG AAT TCT ATT CTC AAT CCA ATC AAC 2250
 E F G E K R K N S I L N P I N

* * * * *
 TCT ATA CGA AAA TTT TCC ATT GTG CAA AAG ACT CCC TTA CAA ATG 2295
 S I R K F S I V Q K T P L Q M

AAT GGC ATC GAA GAG GAT TCT GAT GAG CCT TTA GAG AGA AGG CTG 2340
 N G I E E D S D E P L E R R L

TCC TTA GTA CCA GAT TCT GAG CAG GGA GAG GCG ATA CTG CCT CGC 2385
 S L V P D S E Q G E A I L P R

ATC AGC GTG ATC AGC ACT GGC CCC ACG CTT CAG GCA CGA AGG AGG 2430
 I S V I S T G P T L Q A R R R

CAG TCT GTC CTG AAC CTG ATG ACA CAC TCA GTT AAC CAA GGT CAG 2475
 Q S V L N L M T H S V N Q G Q

AAC ATT CAC CGA AAG ACA ACA GCA TCC ACA CGA AAA GTG TCA CTG 2520
 N I H R K T T A S T R K V S L

* * * * *
 GCC CCT CAG GCA AAC TTG ACT GAA CTG GAT ATA TAT TCA AGA AGG 2565
 A P Q A N L T E L D I Y S R R

TTA TCT CAA GAA ACT GGC TTG GAA ATA AGT GAA GAA ATT AAC GAA 2610
 L S Q E T G L E I S E E I N E

GAA GAC TTA AAG GAG TGC CTT TTT GAT GAT ATG GAG AGC ATA CCA 2655
 E D L K E C L F D D M E S I P

GCA GTG ACT ACA TGG AAC ACA TAC CTT CGA TAT ATT ACT GTC CAC 2700
 A V T T W N T Y L R Y I T V H

AAG AGC TTA ATT TTT GTG CTA ATT TGG TGC TTA GTA ATT TTT CTG 2745
 K S L I F V L I W C L V I F L

GCA GAG GTG GCT GCT TCT TTG GTT GTG CTG TGG CTC CTT GGA AAC 2790
 A E V A A S L V V L W L L G N

ACT CCT CTT CAA GAC AAA GGG AAT AGT ACT CAT AGT AGA AAT AAC 2835
 T P L Q D K G N S T H S R N N

AGC TAT GCA GTG ATT ATC ACC AGC ACC AGT TCG TAT TAT GTG TTT 2880
 S Y A V I I T S T S S Y Y V F

TAC ATT TAC GTG GGA GTA GCC GAC ACT TTG CTT GCT ATG GGA TTC	2925
<u>Y I Y V G V A D T L L A M G F</u>	
TTC AGA GGT CTA CCA CTG GTG CAT ACT CTA ATC ACA GTG TCG AAA	2970
<u>F R G L P L V H T L I T V S K</u>	
ATT TTA CAC CAC AAA ATG TTA CAT TCT GTT CTT CAA GCA CCT ATG	3015
<u>I L H H K M L H S V L Q A P M</u>	
*	
TCA ACC CTC AAC ACG TTG AAA GCA GGT GGG ATT CTT AAT AGA TTC	3060
<u>S T L N T L K A G G I L N R F</u>	
TCC AAA GAT ATA GCA ATT TTG GAT GAC CTT CTG CCT CTT ACC <u>ATA</u>	3105
<u>S K D I A I L D D L L P L T I</u>	
<u>TTT GAC TTC ATC CAG TTG TTA TTA ATT GTG ATT GGA GCT ATA GCA</u>	3150
<u>F D F I Q L L I V I G A I A</u>	
<u>GTT GTC GCA GTT TTA CAA CCC TAC ATC TTT GTT GCA ACA GTG CCA</u>	3195
<u>V V A V L Q P Y I F V A T V P</u>	
<u>GTG ATA GTG GCT TTT ATT ATG TTG AGA GCA TAT TTC CTC CAA ACC</u>	3240
<u>V I V A F I M L R A Y F L Q T</u>	
TCA CAG CAA CTC AAA CAA CTG GAA TCT GAA GGC AGG AGT CCA ATT	3285
<u>S Q Q L K Q L E S E G R S P I</u>	
* * *	
TTC ACT CAT CTT GTT ACA AGC TTA AAA GGA CTA TGG ACA CTT CGT	3330
<u>F T H L V T S L K G L W T L R</u>	
GCC TTC GGA CGG CAG CCT TAC TTT GAA ACT CTG TTC CAC AAA GCT	3375
<u>A F G R Q P Y F E T L F H K A</u>	
* *	
CTG AAT TTA CAT ACT GCC AAC TGG TTC TTG TAC CTG TCA ACA CTG	3420
<u>L N L H T A N W F L Y L S T L</u>	
<u>CGC TGG TTC CAA ATG AGA ATA GAA ATG ATT TTT GTC ATC TTC TTC</u>	3465
<u>R W F Q M R I E M I F V I F F</u>	
<u>ATT GCT GTT ACC TTC ATT TCC ATT TTA ACA ACA GGA GAA GGA GAA</u>	3510
<u>I A V T F I S I L T T G E G E</u>	
GGA AGA <u>GTT GGT ATT ATC CTG ACT TTA GCC ATG AAT ATC ATG AGT</u>	3555
<u>G R V G I I L T L A M N I M S</u>	
ACA TTG CAG TGG GCT GTA AAC TCC AGC ATA GAT GTG GAT AGC TTG	3600
<u>T L Q W A V N S S I D V D S L</u>	
ATG CGA TCT GTG AGC CGA GTC TTT AAG TTC ATT GAC ATG CCA ACA	3645
<u>M R S V S R V F K F I D M P T</u>	

*

GAA GGT AAA CCT ACC AAG TCA ACC AAA CCA TAC AAG AAT GGC CAA 3690
 E G K P T K S T K P Y K N G Q

CTC TCG AAA GTT ATG ATT ATT GAG AAT TCA CAC GTG AAG AAA GAT 3735
 L S K V M I I E N S H V K K D

* * *

GAC ATC TGG CCC TCA GGG GGC CAA ATG ACT GTC AAA GAT CTC ACA 3780
 D I W P S G G Q M T V K D L T

GCA AAA TAC ACA GAA GGT GGA AAT GCC ATA TTA GAG AAC ATT TCC 3825
 A K Y T E G G N A I L E N I S

TTC TCA ATA AGT CCT GGC CAG AGG GTG GGC CTC TTG GGA AGA ACT 3870
F S I S P G Q R V G L L G R T

*

GGA TCA GGG AAG AGT ACT TTG TTA TCA GCT TTT TTG AGA CTA CTG 3915
G S G K S T L L S A F L R L L

AAC ACT GAA GGA GAA ATC CAG ATC GAT GGT GTG TCT TGG GAT TCA 3960
N T E G E I Q I D G V S W D S

ATA ACT TTG CAA CAG TGG AGG AAA GCC TTT GGA GTG ATA CCA CAG 4005
I T L O O W R K A F G V I P Q

*

AAA GTA TTT ATT TTT TCT GGA ACA TTT AGA AAA AAC TTG GAT CCC 4050
K V F I F S G T F R K N L D P

TAT GAA CAG TGG AGT GAT CAA GAA ATA TGG AAA GTT GCA GAT GAG 4095
Y E O W S D Q E I W K V A D E

GTT GGG CTC AGA TCT GTG ATA GAA CAG TTT CCT GGG AAG CTT GAC 4140
V G L R S V I E Q F P G K L D

TTT GTC CTT GTG GAT GGG GGC TGT GTC CTA AGC CAT GGC CAC AAG 4185
F V L V D G G C V L S H G H K

CAG TTG ATG TGC TTG GCT AGA TCT GTT CTC AGT AAG GCG AAG ATC 4230
O L M C L A R S V L S K A K I

TTG CTG CTT GAT GAA CCC AGT GCT CAT TTG GAT CCA GTA ACA TAC 4275
L L L D E P S A H L D P V T Y

*

CAA ATA ATT AGA AGA ACT CTA AAA CAA GCA TTT GCT GAT TGC ACA 4320
O I I R R T L K Q A F A D C T

GTA ATT CTC TGT GAA CAC AGG ATA GAA GCA ATG CTG GAA TGC CAA 4365
V I L C E H R I E A M L E C Q

CAA TTT TTG GTC ATA GAA GAG AAC AAA GTG CGG CAG TAC GAT TCC 4410
 Q F L V I E E N K V R Q Y D S

ATC CAG AAA CTG CTG AAC GAG AGG AGC CTC TTC CGG CAA GCC ATC 4455
 I Q K L L N E R S L F R Q A I

*

AGC CCC TCC GAC AGG GTG AAG CTC TTT CCC CAC CGG AAC TCA AGC 4500
 S P S D R V K L F P H R N S S

AAG TGC AAG TCT AAG CCC CAG ATT GCT GCT CTG AAA GAG GAG ACA 4545
 K C K S K P Q I A A L K E E T

GAA GAA GAG GTG CAA GAT ACA AGG CTT TAGAGAGCAGCATAAATG 4590
 E E E V Q D T R L

TTGACATGGGACATTTGCTCATGGAATTGGAGCTCGTGGACAGT 4635

CACCTCATGGAATTGGAGCTCGTGGACAGTTACCTCTGCCTCAG 4680

AAAACAAGGATGAATTAAGTTTTTTAAAAAGAACATTGG 4725

TAAGGGGAATTGAGGACACTGATATGGGTCTTGATAATGGCTTC 4770

CTGGCAATAGTCAAATTGTGTGAAAGGTACTTCAAATCCTTGAAG 4815

ATTTACCACTTGTGTTTCAAGCCAGATTTCTGAAAACCCCTT 4860

GCCATGTGCTAGTAATTGAAAGGCAGCTCTAAATGTCAATCAGC 4905

CTAGTTGATCAGCTTATTGCTAGTGAAACTCGTTAATTGAGT 4950

GTTGGAGAAGAACTGAAATCATACTTCTTAGGGTTATGATTAAGT 4995

AATGATAACTGGAAACTTCAGCGGTTATATAAGCTGTATTCTT 5040

TTTCTCTCTCTCCCCATGATGTTAGAAACACAACATATTGT 5085

TTGCTAAGCATTCCAACATCTCATTCCAAGCAAGTATTAGAAT 5130

ACCACAGGAACCACAAGACTGCACATCAAATATGCCCTTCAA 5175

CATCTAGTGAGCAGTCAGGAAAGAGAACTTCCAGATCCTGGAAAT 5220

CAGGGTTAGTATTGTCCAGGTCTACCAAAATCTCAATATTCAG 5265

ATAATCACAATACATCCCTTACCTGGAAAGGGCTGTTATAATCT 5310

TTCACAGGGGACAGGATGGTCCCTTGATGAAGAAGTTGATATGC 5355

CTTTCCCAACTCCAGAAAGTGAAGCAGTCACAGACCTTGAAC 5400

AGAGTTAGCTGGAAAAGTATGTTAGTGAAATTGTCACAGGACA 5445

GCCCTTCTTCCACAGAAGCTCCAGGTAGAGGGTGTAAAGTACA 5490

TAGGCCATGGGCACTGTGGGTAGACACACATGAAGTCCAAGCATT 5535
TAGATGTATAGGTTGATGGTGGTATGTTTCAGGCTAGATGTATG 5580
TACCTCATGCTGTCTACACTAAGAGAGAATGAGAGACACACTGAA 5625
GAAGCACCAATCATGAATTAGTTTATATGCTTCTGTTTATAAT 5670
TTTGTGAAGCAAAATTTTCTCTAGGAAATATTATTTAATAA 5715
TGTTTCAAACATATATTACAATGCTGTATTTAAAAGAATGATTA 5760
TGAATTACATTGTATAAAATAATTTATATTGAAATATTGAC 5805
TTTTTATGGCACTAGTATTTTATGAAATATTATGTTAAACTGG 5850
GACAGGGGAGAACCTAGGGTGTATTAACCAGGGGCCATGAATCA 5895
CCTTTGGTCTGGAGGGAGCCCTGGGGCTGATCGAGTTGGCC 5940
CACAGCTGTATGATTCCCAGCCAGACACAGCCTCTTAGATGCAGT 5985
TCTGAAGAAGATGGTACCAACCAGTCTGACTGTTCCATCAAGGGT 6030
ACACTGCCTCTCAACTCCAAACTGACTCTTAAGAAGACTGCATT 6075
ATATTATTACTGTAAGAAAATACTTGTCAATAAAATCCATA 6120
CATTGTGTAAAAAAAAAAAAAA

WE CLAIM:

1. A method of treatment of a defect in the gene for CFTR in a target cell comprising the steps of:

- 5 a) providing a normal CFTR gene; and
- b) transferring in the normal CFTR gene into the cell under conditions favorable for transfer and complementation.

2. The method of Claim 1, wherein the step of transferring further comprises the step of viral vector-mediated gene transfer.

3. The method of Claim 1, wherein the step of transferring further 10 comprises the step of plasmid vector-mediated gene transfer.

4. The method of Claim 1, wherein the step of transferring further comprises the step of lipofection.

5. The method of Claim 2, wherein the step of transferring further comprises the step of DNA protein complex-mediated gene transfer.

15 6. The method of Claim 1, wherein the target cell is an epithelial cell.

7. The method of Claim 2, wherein the virus of the step of viral-mediated gene transfer comprises a retrovirus.

8. The method of Claim 6, wherein the epithelial cell is an airway epithelial cell.

20 9. The method of Claim 6, wherein the epithelial cell is pancreatic cell.

10. The method of Claim 6, wherein the epithelial cell is selected from a group consisting of sweat gland, intestinal, liver and kidney cells.

11. The method of Claim 7, wherein the retrovirus is replication-defective.

12. A recombinant viral vector for treating a defect in the gene for CFTR in 25 a target cell, the vector comprising:

a) the DNA of at least a portion of the genome of a virus which portion is capable of infecting the target cell; and

b) a normal CFTR gene operatively linked to the DNA portion of the viral genome and capable of expression in the target cell *in vivo* or *in vitro*.

30 13. The recombinant vector of Claim 12, wherein the virus is a retrovirus.

14. The recombinant vector of Claim 13, wherein the retroviral genome is replication-defective.

15. The recombinant vector of Claim 13, further comprising PLJ.

16. The recombinant vector of Claim 15, wherein the vector provirus is substantially as shown in Figure 1A.

17. The recombinant vector of Claim 13, wherein the defect being treated causes cystic fibrosis.

5 18. The recombinant vector of Claim 12, wherein the target cell is an epithelial cell.

19. The recombinant vector of Claim 17, wherein the epithelial cell is pancreatic.

20. The recombinant vector of Claim 17, wherein the epithelial cell is an 10 airway epithelial cell.

21. The recombinant vector of Claim 17, wherein the epithelial cell is a cell selected from the group consisting of sweat gland, intestinal, liver and kidney cells.

22. The recombinant vector of Claim 18, further comprising PLJ.

23. The recombinant vector of Claim 19, further comprising PLJ.

15 24. The recombinant vector of Claim 15, wherein the normal CFTR gene contains silent mutations stabilizing expression.

25. A method of treating cystic fibrosis in a patient comprising the steps of:
a) providing a recombinant viral vector comprising DNA of at least 20 a portion of a retroviral genome, which portion is capable of infecting an epithelial cell and a normal CFTR gene operatively linked thereto and capable of expression in the target cell; and

b) contacting an epithelial cell population of the patient under conditions favorable for transduction for a time sufficient for transduction to occur in at least a portion of the cell population contacted.

25 26. The method of Claim 25, wherein the contacting is done *in vivo*.

27. The method of Claim 25, wherein the recombinant viral vector is replication-defective.

28. The method of Claim 25, wherein the cell population comprises pancreatic cells.

30 29. The method of Claim 25, wherein the cell population comprises airway epithelial cells.

30. The method of Claim 25, wherein the cell population comprises a cell population selected from the group consisting of sweat gland cells, intestinal cells, liver cells and kidney cells.

31. The method of Claim 25, wherein the cell population is contacted *in vitro* and at least of portion thereof is introduced into the patient after transduction.

32. The method of Claim 27, wherein the recombinant retroviral vector comprises PLJ.

5 33. A CF cell which expresses a normal CFTR gene introduced therein through retroviral transduction.


34. The cell of Claim 23, wherein the cell is derived from a PLJ-CFTR clone selected from the group consisting of PLJ-CFTR clone 1 and 3 through 20.


35. A complementation assay for a nucleic acid sequence comprising a 10 putatively defective CFTR gene, the assay comprising:


- a) a CFTR defective cell population;
- b) a recombinant vector capable of infecting and transferring a CFTR gene to the CFTR defective cell population and carrying the nucleic acid sequence being assayed;
- c) means for screening for the presence and/or level of CFTR function in the cell population after infection by the recombinant vector.

36. A method of assaying for putative CF mutations in a nucleic acid sequence, the method comprising the steps of:

- a) providing a vector recombined with the nucleic acid sequence;
- b) providing a CFTR defective cell population;
- c) infecting the CFTR defective cell population with the recombined vector under conditions favorable to transduction for a time sufficient for transduction to occur; and
- d) screening for complementation of CFTR function in the 25 transduced cell population after infection.







4/8










Fig. 1A.











Normal CFTR exon 6b sequence CAGAAATGATTGAAAATATCCAATCT...

CFTR BQ exon 6b sequence CAGAAATGATCGAGAACATCCAATCT...



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/06660

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC
 IPC(5): C12P 21/06; C12N 5/00, 15/00; A61K 49/00; C12Q 1/68
 U.S.C1.: 435/69.1, 240.26, 172.2, 173.3; 424/9; 435/6

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System	Classification Symbols
U.S.C1.	435/69.1, 172.2, 173.3, 240.26; 424/9; 435/6

Documentation Searched other than Minimum Documentation
 to the Extent that such Documents are Included in the Fields Searched ⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y,P	US,A, 4,980,286 (Morgan et al.) 25 December 1990, see all document.	1-11, 33-34
Y	US,A,4,868,116 (Morgan et al.) 19 September 1989, see all documents.	33-34
A,P	Science, Vol. 250, issued 05 October 1990, Green et al "Chromosomal region of the cystic fibrosis gene in yeast artificial chromosome: a model for the human genome mapping", pp. 94-98, see entire document.	1-11, 25-36
Y A	Science, Vol. 235, issued 27 February 1987, Collins et al. "Construction of a general human chromosome jumping library with application to cystic fibrosis", pp. 1047-1049, see entire document.	25-32 1-11, 33-36
A	Science, Vol. 230, issued 29 November 1985, Tsui et al. "Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker", pages 1054-1057, see entire document.	1-11, 25-36

- Special categories of cited documents: ¹⁰
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
01 January 1992	05 FEB 1992
International Searching Authority	Signature of Authorized Officer
ISA/US	Miquel Escallón, Ph.D.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	Genomics, Vol. 2, issued 1988, Drumm et al., "Physical mapping of the cystic fibrosis region by pulse-field gel electrophoresis", pages 346-354, see pages 350-352.	1-11, 25-36
A	Science, Vol. 233, issued August 1986, Fritzzell et al., "Altered regulation of airway epithelia cell chloride channel in cystic fibrosis", pages 358-360, see entire document.	1-11, 25-36
A	Nature, Vol. 322, issued 31 July 1986, Welsh et al., "Chloride channels in cystic fibrosis airway epithelia", pages 468-470, see entire document.	1-11, 25-36
A/Y	"Genetics and Epithelia Cell Dysfunction in cystic fibrosis," published 1987 by Allan R. Liss, Inc. pages 59-71, see entire document.	<u>1-11, 25-32, 35, 36</u> 33-34
A/Y	The Journal of Cell Biology, Vol. 107, No. 6, issued 1989, Jensen et al., "Chloride channel in culture sweat cell gland epithelia in cystic fibrosis", see abstract 788.	<u>1-11, 25-32, 35, 36</u> 33-34
A/Y	Proceedings of the National Academy of Science USA, Vol. 82, issued October 1983, Sttuts et al., "Chloride uptake into cultured airway epithelia cells from cystic fibrosis patients and normal individuals", pages 6677-6687, see entire document.	<u>1-11, 25-32, 35-36</u> 33-34
A/Y	The Journal of Cell Science, Vol. 87, issued 1987, Harris et al., "Establishment of a tissue culture for epithelia cells derived from human pancreas: a model for the study of cystic fibrosis", pages 695-703, see entire document.	<u>1-11, 25-32, 35, 36</u> 33-34
A	In Vitro Cellular and Developmental Biology, Vol. 21, No. 10, issued October 1985, Collie et al., "Culture of sweat gland epithelia cells from normal individuals and patients with cystic fibrosis", pages 597-602, see entire document.	1-11, 25-36
A	Science, Vol. 245, issued 08 September 1989, Rammens et al. "Identification of the cystic fibrosis gene: chromosome walking and jumping", pages 1059-1065, see entire document.	1-11, 25-36

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE 1

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers _____, because they relate to subject matter¹² not required to be searched by this Authority, namely:

2. Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹³, specifically:

3. Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 2

This International Searching Authority found multiple inventions in this international application as follows:

SEE ATTACHMENT

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims: 1-11, 25-32, 33-36

telephone practice

3. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

The additional search fees were accompanied by applicant's protest.

No protest accompanied the payment of additional search fees.